当前位置：
X-MOL 学术
›
Diabetes Obes. Metab.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Safety of dapagliflozin in a broad population of patients with type 2 diabetes: Analyses from the DECLARE-TIMI 58 study.
Diabetes, Obesity and Metabolism ( IF 5.4 ) Pub Date : 2020-04-02 , DOI: 10.1111/dom.14041 Avivit Cahn 1 , Itamar Raz 1 , Marc Bonaca 2 , Ofri Mosenzon 1 , Sabina A Murphy 2 , Ilan Yanuv 1 , Aliza Rozenberg 1 , John P H Wilding 3 , Deepak L Bhatt 2 , Darren K McGuire 4 , Ingrid A M Gause-Nilsson 5 , Martin Fredriksson 5 , Peter A Johansson 5 , Gyorgy Jermendy 6 , Samy Hadjadj 7 , Anna Maria Langkilde 5 , Marc S Sabatine 2 , Stephen D Wiviott 2 , Lawrence A Leiter 8
Diabetes, Obesity and Metabolism ( IF 5.4 ) Pub Date : 2020-04-02 , DOI: 10.1111/dom.14041 Avivit Cahn 1 , Itamar Raz 1 , Marc Bonaca 2 , Ofri Mosenzon 1 , Sabina A Murphy 2 , Ilan Yanuv 1 , Aliza Rozenberg 1 , John P H Wilding 3 , Deepak L Bhatt 2 , Darren K McGuire 4 , Ingrid A M Gause-Nilsson 5 , Martin Fredriksson 5 , Peter A Johansson 5 , Gyorgy Jermendy 6 , Samy Hadjadj 7 , Anna Maria Langkilde 5 , Marc S Sabatine 2 , Stephen D Wiviott 2 , Lawrence A Leiter 8
Affiliation
To evaluate comprehensively the safety of dapagliflozin in patients with type 2 diabetes (T2DM), with emphasis placed on potential safety concerns related to the sodium‐glucose co‐transporter‐2 inhibitor class.
中文翻译：
达格列净在广泛的2型糖尿病患者中的安全性：DECLARE-TIMI 58研究的分析结果。
要全面评估达格列净在2型糖尿病（T2DM）患者中的安全性，重点在于与钠-葡萄糖共转运蛋白2抑制剂类别有关的潜在安全性问题。
更新日期：2020-04-02
中文翻译：
达格列净在广泛的2型糖尿病患者中的安全性：DECLARE-TIMI 58研究的分析结果。
要全面评估达格列净在2型糖尿病（T2DM）患者中的安全性，重点在于与钠-葡萄糖共转运蛋白2抑制剂类别有关的潜在安全性问题。
京公网安备 11010802027423号